J parathyr dis. 2017;5(2): 87-90.
doi: 10.15171/jpd.2018.27
  Abstract View: 361
  PDF Download: 178


Cholecalciferol versus calcitriol to manage secondary hyperparathyroidism in hemodialysis patients

Hamid Reza Omrani 1, Ali Daraizade 2*

1 Nephrology and Urology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
2 Department of Internal Medicine, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran.
*Corresponding author: Ali Daraizade, hamidomrani@ymail.com


Introduction: Secondary hyperparathyroidism, is a matter of concern in hemodialysis patients that cause renal osteodystrophy eventually.

Objectives: The objective of the study was to compare the efficacy of cholecalciferol with calcitriol for treating secondary hyperparathyroidism.

Materials and Methods: This study is a randomized, controlled study. Around 80 patients with hyperparathyroidism (PTH >300 ρg/ mL) and 25(OH)D level <20 ng/mL were divided into two groups to receive cholecalciferol 50 000 IU/3 times in one week or calcitriol 0.25 μg/daily for 12 weeks. Additionally calcium carbonate 1000-1500 mg/d/tablets is prescribed for both groups. Reduction of parathyroid hormone (PTH), changes of plasma albumin-corrected calcium and phosphorus and levels of 25(OH)D were analyzed.

Results: Around 40 patients were randomized into each group. At baseline, plasma albumin-corrected calcium, phosphorus and intact PTH and 25(OH)D had no difference between groups. At week 12, intact PTH levels in cholecalciferol and calcitriol groups were 242.38±16.38 ρg/mL and 237.84±13.65 ρg/mL in respectively. Patients who achieved target intact PTH of <300 ρg/mL were 90% in the cholecalciferol and 95% in the calcitriol group (P = 0.447). Serum calcium and phosphorus were not significantly different in both groups. Serum calcium; 9.07±0.36 mg/dL versus 9.00 ± 0.38 mg/dL (P = 0.607), phosphorus; 4.81±0.55 mg/dL versus 4.15 ± 0.42 mg/dL (P = 0.126) in cholecalciferol and calcitriol groups respectively. Furthermore, serum 25(OH)D levels significantly rise in cholecalciferol group. Serum 25(OH)D levels were 62.98 ±21.03 ng/mL in cholecalciferol group and 18.95±22.70 ng/mL in calcitriol group (P < 0.05).

Conclusion: cholecalciferol can be administered to control secondary hyperparathyroidism and vitamin D(25OH) deficiency in hemodialysis patients . The two drugs are equally efficacious and lead to similar changes in calcium and phosphorus levels.

Keywords: Hyperparathyroidism, Hemodialysis, Cholecalciferol, Calcitriol
Please cite this paper as: Omrani HR, Daraizade A. Cholecalciferol versus calcitriol to manage secondary hyperparathyroidism in hemodialysis patients. J Parathyr Dis. 2018;6(2):87-90. doi: 10.15171/jpd.2018.27.
First Name
Last Name
Email Address
Security code

Abstract View: 361

Your browser does not support the canvas element.

PDF Download: 178

Your browser does not support the canvas element.

ePublished: 04 Jan 2018
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)